Want to see CLYM full AI Analyst Report?

Climb Bio (CLYM) Price & Analysis

723 Followers

CLYM Stock Chart & Stats

$12.84

-$0.05(-0.39%)

At close: Jul 27 4:00 PM EDT

$12.84

-$0.05(-0.39%)

Day’s Range― - ―

52-Week Range$1.36 - $14.42

Previous Close$12.82

Volume1.21M

Average Volume (3M)1.35M

Market Cap

$681.43M

Enterprise Value$358.14

Total Cash (Recent Filing)$109.56M

Total Debt (Recent Filing)$479.00K

Price to Earnings (P/E)―

Beta1.55

Next Earnings

Aug 18, 2026

EPS Estimate

-0.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.78

Shares Outstanding57,263,023

10 Day Avg. Volume1,017,170

30 Day Avg. Volume1,347,738

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)1.69

Price to Sales (P/S)0.00

P/FCF Ratio-4.97

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$22.71

Price Target Upside76.90% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-0.87

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageMinimal debt materially reduces solvency and interest burden for a pre-revenue biotech. Low leverage lengthens optionality and gives management time to progress multiple trials without high fixed financing costs, lowering structural bankruptcy and liquidity risk over the next several quarters.

Promising Budoprutug Clinical SignalsDurable biologic activity and a clean safety signal in heavily pretreated ITP patients structurally de-risk the lead program. Positive translational efficacy improves the probability of advancing to larger registrational studies and strengthens long-term commercial potential in B-cell driven autoimmune indications.

Material Recent Capital InfusionA sizeable $110M private placement meaningfully extends runway and funds multi-trial development. Greater near-term liquidity reduces the immediacy of financing risk, enabling steady execution of clinical milestones which are the primary drivers of durable value creation for a clinical-stage biotech.

Bears Say

Pre-revenue With Persistent LossesAbsence of product revenue leaves the company dependent on external funding to sustain operations. Persistent operating and net losses mean there is no internal margin improvement to absorb shocks, creating ongoing funding risk and limiting durable margin visibility over the medium term.

Elevated And Rising Cash BurnMaterially negative operating cash flow and intensifying burn heighten dependence on external capital. Sustained high cash outflows increase dilution risk, force prioritization of programs if funds tighten, and slow path-to-self-sustaining operations unless clinical readouts accelerate value realization.

Equity Erosion And Negative ROEDeclining equity and persistently negative ROE reflect shareholder value erosion from recurring losses and financing. Continued dilution compresses per-share upside and can undermine investor support for future raises, placing structural pressure on long-term capital access and stockholder returns.

Climb Bio News

Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst

Climb Bio, Inc. ($CLYM) announced an update on their ongoing clinical study. Climb Bio, Inc. (CLYM) has completed...

4d ago

CLYM

Climb Bio: Unique APRIL Inhibitor Profile Supports Buy Rating and Unchanged $20 Price Target

Climb Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from...

12d ago

CLYM

Climb Bio Appoints Breanna O’Reilly to Board

Climb Bio ( ($CLYM) ) has issued an announcement. On June 29, 2026, Climb Bio, Inc. announced that...

1M ago

CLYM

Climb Bio Buy Rating Reiterated as Advancing Pipeline Supports Maintained $20 Price Target

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Climb Bio, with...

1M ago

CLYM

Climb Bio Establishes New At-the-Market Equity Program

Climb Bio ( ($CLYM) ) has provided an announcement. On June 12, 2026, Climb Bio, Inc. entered into...

2M ago

CLYM

Climb Bio price target raised to $20 from $19 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on Climb Bio (CLYM) to $20 from $19 and...

2M ago

CLYM

Climb Bio announces initial data from budoprutug study at EHA

Climb Bio (CLYM) announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating...

2M ago

CLYM

Climb Bio Reports Encouraging Early Budoprutug ITP Data

Climb Bio ( ($CLYM) ) has shared an update. On June 11, 2026, Climb Bio, Inc. reported initial...

2M ago

CLYM

Climb Bio Shareholders Approve Equity Plan Amendment, Reelect Directors

Climb Bio ( ($CLYM) ) has provided an announcement. At Climb Bio’s 2026 Annual Meeting of Stockholders held...

2M ago

CLYM

Climb Bio initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Climb Bio (CLYM) with a Buy rating and $35 price target. Lead asset budoprutug...

2M ago

AMGN

CLYM

Julian Harrison Reiterates Buy on CLYM116, Maintains $19 Price Target on Best-in-Class IgAN Potential

Analyst Julian Harrison of BTIG maintained a Buy rating on Climb Bio, retaining the price target of $19.00....

2M ago

CLYM

Climb Bio Reports Positive Early-Stage Data for CLYM116

An update from Climb Bio ( ($CLYM) ) is now available. On June 5, 2026, Climb Bio reported...

2M ago

CLYM

Climb Bio registers to sell 11.59M shares of common stock for holders

This filing relates to the offer and sale from time to time by the selling stockholder of up...

2M ago

CLYM

Climb Bio price target raised to $20 from $15 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $20 from $15...

3M ago

CLYM

CLYM FAQ

What was Climb Bio, Inc.’s price range in the past 12 months?

Climb Bio, Inc. lowest stock price was $1.36 and its highest was $14.41 in the past 12 months.

What is Climb Bio, Inc.’s market cap?

Climb Bio, Inc.’s market cap is $681.43M.

When is Climb Bio, Inc.’s upcoming earnings report date?

Climb Bio, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 15 days.

How were Climb Bio, Inc.’s earnings last quarter?

Climb Bio, Inc. released its earnings results on May 07, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.088.

Is Climb Bio, Inc. overvalued?

According to Wall Street analysts Climb Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Climb Bio, Inc. pay dividends?

Climb Bio, Inc. does not currently pay dividends.

What is Climb Bio, Inc.’s EPS estimate?

Climb Bio, Inc.’s EPS estimate is -0.21.

How many shares outstanding does Climb Bio, Inc. have?

Climb Bio, Inc. has 57,263,023 shares outstanding.

What happened to Climb Bio, Inc.’s price movement after its last earnings report?

Climb Bio, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -2.537%.

Which hedge fund is a major shareholder of Climb Bio, Inc.?

Currently, no hedge funds are holding shares in CLYM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Climb Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-24.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Climb Bio, Inc.

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Climb Bio (CLYM) Earnings & Revenues

Historic Earnings Reports

CLYM Stock 12 Month Forecast

Average Price Target

$22.71

▲(76.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","27":"$27","36":"$36"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.714285714285715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,9,18,27,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,14.959999999999999,16.63,18.3,19.97,21.64,23.310000000000002,24.98,26.65,28.32,29.990000000000002,31.66,33.33,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,14.014945054945054,14.739890109890109,15.464835164835165,16.189780219780218,16.914725274725274,17.63967032967033,18.364615384615384,19.08956043956044,19.814505494505497,20.53945054945055,21.264395604395606,21.989340659340662,{"y":22.714285714285715,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.29,13.65230769230769,14.014615384615384,14.376923076923076,14.739230769230769,15.10153846153846,15.463846153846154,15.826153846153845,16.18846153846154,16.55076923076923,16.913076923076922,17.275384615384617,17.63769230769231,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.91,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >